Inclusion Criteria:  Recent hospitalization (within 5 weeks of screening) for an acute coronary syndrome Serum LDL-C ≥70 mg/dL Fasting triglycerides <4.52 mmol/L (<400 mg/dL) at screening Calculated glomerular filtration rate >30 mL/min by estimated glomerular filtration rate (eGFR) Participants are required to be discharged on statin therapy, or have documented statin intolerance, as determined by the investigator, following hospitalization for an ACS. Statin intolerant patients are eligible if they had intolerable side effects on at least 2 different statins, including one at the lowest standard dose  Exclusion Criteria:  New York Heart Association (NYHA) class III or IV heart failure or last known left ventricular ejection fraction <30%. Significant cardiac arrhythmia within 3 months prior to randomization that is not controlled by medication or via ablation at the time of screening. Severe concomitant non-cardiovascular disease that carries the risk of reducing life expectancy to less than 2 years. Treatment with other investigational products or devices within 30 days or five half˗lives of the screening visit, whichever is longer. Planned use of other investigational products or devices during the course of the study. Previous or current treatment (within 90 days of screening) with monoclonal antibodies directed towards PCSK9. Recurrent ACS event within 2 weeks prior to randomization. Coronary angiography and revascularization procedure (percutaneous coronary intervention (PCI) or coronary artery bypass grafting (CABG) surgery) performed within 2 weeks prior to the randomization visit or planned after randomization.